A Budget Impact Analysis of the Introduction of Copanlisib for Treatment of Relapsed Follicular Lymphoma in the United States | Zendy

Sreevalsa Appukkuttan | Zendy; Emilie D. Duchesneau | Zendy; Miriam L. Zichlin | Zendy; Rachel H. Bhak | Zendy; Avin Yaldo | Zendy; Mecide Gharibo | Zendy; Svetlana Babajanyan | Zendy; Mei Sheng Duh | Zendy

Open Access

A Budget Impact Analysis of the Introduction of Copanlisib for Treatment of Relapsed Follicular Lymphoma in the United States

Author(s) -

Sreevalsa Appukkuttan,

Emilie D. Duchesneau,

Miriam L. Zichlin,

Rachel H. Bhak,

Avin Yaldo,

Mecide Gharibo,

Svetlana Babajanyan,

Mei Sheng Duh

Publication year - 2019

Publication title -

journal of managed care and specialty pharmacy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.126

H-Index - 63

eISSN - 2376-1032

pISSN - 2376-0540

DOI - 10.18553/jmcp.2019.18259

Subject(s) - formulary , medicine , population , family medicine , health care , follicular lymphoma , lymphoma , environmental health , political science , law

Copanlisib was recently granted accelerated approval by the FDA for the treatment of adult patients with relapsed follicular lymphoma (FL) after 2 previous systemic therapies. It is important to assess the effect that this and other changes in the treatment landscape of relapsed FL have on a payer's budget to inform formulary decisions.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom

About

About Careers Publisher Partners Contact Us Our institutional solutions Get Organisational Trial or Quote

Learn

FAQs Blog Terms of Use Privacy Policy

Download the Zendy App

Discover

Explore

Home ZAIA Blog